Open Orphan #ORPH – £7.3m Influenza human challenge study contract win May 18, 2022 – Posted in: Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £7.3m influenza human challenge study (“Study”) contract with a leading biotechnology company to test its antiviral product using the hVIVO Influenza Human Challenge Study Model.  The randomised, double-blinded, placebo-controlled study will test and assess the antiviral prophylactic and…